Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review)
- Authors:
- Qian-Ru Tao
- Ying-Ming Chu
- Lan Wei
- Chao Tu
- Yuan-Yuan Han
-
Affiliations: Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China, Department of Integrated Traditional Chinese Medicine, Peking University First Hospital, Beijing 100034, P.R. China, Department of Internal Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan 650118, P.R. China - Published online on: February 8, 2021 https://doi.org/10.3892/mmr.2021.11899
- Article Number: 260
-
Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Tanabe K, Maeshima Y, Sato Y and Wada J: Antiangiogenic therapy for diabetic nephropathy. Biomed Res Int. 2017:57240692017. View Article : Google Scholar : PubMed/NCBI | |
|
Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, et al: US renal data system 2010 annual data report. Am J Kidney Dis. 57 (Suppl 1):A8:e1–e526. 2011. View Article : Google Scholar | |
|
Thomas MC, Cooper ME and Zimmet P: Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 12:73–81. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA and Holman RR; UKPDS Group, : Development and progression of nephropathy in type 2 diabetes, the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 63:225–232. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Retnakaran R, Cull CA, Thorne KI, Adler AI and Holman RR; UKPDS Study Group, : Risk factors for renal dysfunction in type 2 diabetes, U.K. prospective diabetes study 74. Diabetes. 55:1832–1839. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bayliss G, Weinrauch LA and D'Elia JA: Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep. 12:440–446. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske BL, Kutner N, Liu J, et al: US renal data system 2013 annual data report. Am J Kidney Dis. 63 (Suppl 1):A72014. View Article : Google Scholar : PubMed/NCBI | |
|
Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C and Egido J: Therapeutic approaches to diabetic nephropathy-beyond the RAS. Nat Rev Nephrol. 10:325–346. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M and Garcia-Perez J: Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 7:327–340. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tuttle KR: Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 16:1537–1538. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wada J and Makino H: Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 12:13–26. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H and Watanabe T: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 45:288–294. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hanna RM, Abdelnour L, Hasnain H, Selamet U and Kurtz I: Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. SAGE Open Med Case Rep. 8:2050313X209070332020.PubMed/NCBI | |
|
Satchell SC, Anderson KL and Mathieson PW: Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol. 15:566–574. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tsilibary EC: Microvascular basement membranes in diabetes mellitus. J Pathol. 200:537–546. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W and Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 12:993–1000. 2001.PubMed/NCBI | |
|
Filek R, Hooper P, Sheidow TG, Liu H, Chakrabarti S and Hutnik CM: Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 13:1097–1114. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, Sonoda H, Sato Y and Makino H: Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes. 58:2365–2375. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA and Hugo CP: Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 69:1654–1661. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Osterby R and Nyberg G: New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1:122–127. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Osterby R, Bangstad HJ, Nyberg G and Rudberg S: On glomerular structural alterations in type-1 diabetes. Companions of early diabetic glomerulopathy. Virchows Arch. 438:129–135. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wang DQ, Miao XJ, Gao J, Zhou YH, Ji FY and Cheng XB: The 150-kDa oxygen-regulated protein (ORP150) regulates proteinuria in diabetic nephropathy via mediating VEGF. Exp Mol Pathol. 110:1042552019. View Article : Google Scholar : PubMed/NCBI | |
|
Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS and Chen S: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol. 17:3093–3104. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG and Rasch R: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 51:3090–3094. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH and De Vriese AS: A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant. 21:324–329. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wen D, Huang X, Zhang M, Zhang L, Chen J, Gu Y and Hao CM: Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One. 8:e823362013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin S, Teng J, Li J, Sun F, Yuan D and Chang J: Association of chemerin and vascular endothelial growth factor (VEGF) with diabetic nephropathy. Med Sci Monit. 22:3209–3214. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H and Kurtz I: Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: Emerging evidence. Kidney Int. 96:572–580. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Oe Y, Fushima T, Sato E, Sekimoto A, Kisu K, Sato H, Sugawara J, Ito S and Takahashi N: Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury. Sci Rep. 9:29862019. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ and Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 48:2229–2239. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK and Won NH: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl. 77:S104–S112. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E and Bruijn JA: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 43:636–650. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hanefeld M, Appelt D, Engelmann K, Sandner D, Bornstein SR, Ganz X, Henkel E, Haase R and Birkenfeld AL: Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy. Horm Metab Res. 48:529–534. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shao Y, Lv C, Yuan Q and Wang Q: Levels of Serum 25(OH)VD3, HIF-1α, VEGF, vWf, and IGF-1 and their correlation in type 2 diabetes patients with different urine albumin creatinine ratio. J Diabetes Res. 2016:19254242016. View Article : Google Scholar : PubMed/NCBI | |
|
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH and Quaggin SE: Glomerular- specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 111:707–716. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, Welsh GI, Richards A, Usui Y, Satchell SC, et al: VEGF regulates local inhibitory complement proteins in the eye and kidney. J Clin Invest. 127:199–214. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, Nagata M, Watanabe T and Fan J: Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol. 18:2094–2104. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 358:1129–1136. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB and Tufro A: Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 77:989–999. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sato W, Tanabe K, Kosugi T, Hudkins K, Lanaspa MA, Zhang L, Campbell-Thompson M, Li Q, Long DA, Alpers CE and Nakagawa T: Selective stimulation of VEGFR2 accelerates progressive renal disease. Am J Pathol. 179:155–166. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Stevens M, Neal CR, Craciun EC, Dronca M, Harper SJ and Oltean S: The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy. PLoS One. 14:e02129102019. View Article : Google Scholar : PubMed/NCBI | |
|
Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Bates DO and Curry FE: Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol. 273:H687–H694. 1997.PubMed/NCBI | |
|
Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A and Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:3336–3343. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Guo D, Jia Q, Song HY, Warren RS and Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem. 270:6729–6733. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 273:30336–30343. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Nakagawa T, Sato W, Kosugi T and Johnson RJ: Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res. 2013:1845392013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakagawa T: Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: An explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol. 292:F1665–F1672. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Muhl L, Moessinger C, Adzemovic MZ, Dijkstra MH, Nilsson I, Zeitelhofer M, Hagberg CE, Huusko J, Falkevall A, Ylä-Herttuala S and Eriksson U: Expression of vascular endothelial growth factor (VEGF)-B and its receptor (VEGFR1) in murine heart, lung and kidney. Cell Tissue Res. 365:51–63. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Falkevall A, Mehlem A, Palombo I, Heller Sahlgren B, Ebarasi L, He L, Ytterberg AJ, Olauson H, Axelsson J, Sundelin B, et al: Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab. 25:713–726. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Lan D, Li T, Yang G and Liu L: Angiopoietins regulate vascular reactivity after haemorrhagic shock in rats through the Tie2-nitric oxide pathway. Cardiovasc Res. 96:308–319. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KL, Shin IS, Kim JM, Choi JH, Byun J, Jeon ES, Suh W and Kim DK: Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc Res. 72:394–402. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dessapt-Baradez C, Woolf AS, White KE, Pan J, Huang JL, Hayward AA, Price KL, Kolatsi-Joannou M, Locatelli M, Diennet M, et al: Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol. 25:33–42. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao L, Lu SL, Dong JY and Song F: Abnormal regulation of neo-vascularisation in deep partial thickness scalds in rats with diabetes mellitus. Burns. 37:1015–1022. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH, Yasunaga K, Kim KT, Kim I, Choi HH, et al: COMP-Ang1, a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci USA. 101:5547–5552. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang KY, Lee SY, Park BH, Koh GY and Park SK: Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant. 22:396–408. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K and Malik AB: Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol. 289:L371–L381. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ and Stewart DJ: Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol. 162:1927–1936. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Nakagawa T, Kosugi T, Haneda M, Rivard CJ and Long DA: Abnormal angiogenesis in diabetic nephropathy. Diabetes. 58:1471–1478. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liang G, Song L, Chen Z, Qian Y, Xie J, Zhao L, Lin Q, Zhu G, Tan Y, Li X, et al: Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney Int. 93:95–109. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J and Shulman GI: FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Commun. 6:69802015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Lei T, Huang JF, Wang SB, Zhou LL, Yang ZQ and Chen XD: The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol. 342:41–47. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Wang X, Wang ZY and Li L: Circ_0080425 inhibits cell proliferation and fibrosis in diabetic nephropathy via sponging miR-24-3p and targeting fibroblast growth factor 11. J Cell Physiol. 235:4520–4529. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lin S, Yu L, Ni Y, He L, Weng X, Lu X and Zhang C: Fibroblast growth factor 21 attenuates diabetes-induced renal fibrosis by negatively regulating TGF-β-p53-Smad2/3-mediated epithelial-to-mesenchymal transition via activation of AKT. Diabetes Metab J. 44:158–172. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Suassuna PGA, de Paula RB, Sanders-Pinheiro H, Moe OW and Hu MC: Fibroblast growth factor 21 in chronic kidney disease. J Nephrol. 32:365–377. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Esteghamati A, Khandan A, Momeni A, Behdadnia A, Ghajar A, Nikdad MS, Noshad S, Nakhjavani M and Afarideh M: Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease. Ir J Med Sci. 186:785–794. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, Song HK, Nam DH, Han JY, Han SY, et al: Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology. 154:3366–3376. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Guo X, Zhang T, Wang N, Li J, Xu P, Zhang S, Ren G and Li D: Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway. Biomed Pharmacother. 93:695–704. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kuro-O M: Klotho in health and disease. Curr Opin Nephrol Hypertens. 21:362–368. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yeung SMH, Bakker SJL, Laverman GD and De Borst MH: Fibroblast growth factor 23 and adverse clinical outcomes in type 2 diabetes: A bitter-sweet symphony. Curr Diab Rep. 20:502020. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, Ni Z, Zhang B, Zhang D, Luo F, et al: FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 5:1812020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao L, Zou Y and Liu F: Transforming growth factor-beta1 in diabetic kidney disease. Front Cell Dev Biol. 8:1872020. View Article : Google Scholar : PubMed/NCBI | |
|
Steele FR, Chader GJ, Johnson LV and Tombran-Tink J: Pigment epithelium-derived factor, neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA. 90:1526–1530. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Becerra SP, Palmer I, Kumar A, Steele F, Shiloach J, Notario V and Chader GJ: Overexpression of fetal human pigment epithelium-derived factor in Escherichia coli. A functionally active neurotrophic factor. J Biol Chem. 268:23148–23156. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W and Bouck NP: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science. 285:245–248. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ogata N, Matsuoka M, Matsuyama K, Shima C, Tajika A, Nishiyama T, Wada M, Jo N, Higuchi A, Minamino K, et al: Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab. 92:1176–1179. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Park K, Jin J, Hu Y, Zhou K and Ma JX: Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol. 178:688–698. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, Cristofalo V, Hammes HP, Smith G, Boulton M and Pfeiffer AF: Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes. 50:2641–2645. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gao G, Li Y, Zhang D, Gee S, Crosson C and Ma J: Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 489:270–276. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang SX, Wang JJ, Gao G, Shao C, Mott R and Ma JX: Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 20:323–325. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Park K, Lee K, Zhang B, Zhou T, He X, Gao G, Murray AR and Ma JX: Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol. 31:3038–3051. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu M, Boulton M, Lyons TJ, Gao G and Ma JX: Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol. 175:2676–2685. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Konson A, Pradeep S, D'Acunto CW and Seger R: Pigment epithelium-derived factor and its phosphomimetic mutant induce JNK-Dependent apoptosis and P38-mediated migration arrest. Cell Physiol Biochem. 49:512–529. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Duh EJ, Caldwell RB and Behzadian MA: Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression. Invest Ophthalmol Vis Sci. 51:3273–3280. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Notari L, Arakaki N, Mueller D, Meier S, Amaral J and Becerra SP: Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase. FEBS J. 277:2192–2205. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cai J, Wu L, Qi X, Li Calzi S, Caballero S, Shaw L, Ruan Q, Grant MB and Boulton ME: PEDF regulates vascular permeability by a ү-secretase-mediated pathway. PLoS One. 6:e211642011. View Article : Google Scholar : PubMed/NCBI | |
|
Chai KX, Ma JX, Murray SR, Chao J and Chao L: Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem. 266:16029–16036. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Miao RQ, Agata J, Chao L and Chao J: Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 100:3245–3252. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Jenkins AJ, McBride JD, Januszewski AS, Karschimkus CS, Zhang B, O'Neal DN, Nelson CL, Chung JS, Harper CA, Lyons TJ and Ma JX: Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res. 2:192010. View Article : Google Scholar : PubMed/NCBI | |
|
McBride JD, Jenkins AJ, Liu X, Zhang B, Lee K, Berry WL, Janknecht R, Griffin CT, Aston CE, Lyons TJ, et al: Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol. 134:1725–1734. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Zhang B, McBride JD, Zhou K, Lee K, Zhou Y, Liu Z and Ma JX: Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes. 62:4228–4238. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lawler J: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 6:1–12. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA and Roberts DD: Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA. 102:13141–13146. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sorenson CM, Wang S, Gendron R, Paradis H and Sheibani N: Thrombospondin-1 deficiency exacerbates the pathogenesis of diabetic retinopathy. J Diabetes Metab. S12:10.4172/2155-6156.S12-005. 2013. | |
|
Lawler J: The functions of thrombospondin-1 and −2. Curr Opin Cell Biol. 12:634–640. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Armstrong LC and Bornstein P: Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 22:63–71. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mandler WK, Nurkiewicz TR, Porter DW, Kelley EE and Olfert IM: Microvascular dysfunction following multiwalled carbon nanotube exposure is mediated by thrombospondin-1 receptor CD47. Toxicol Sci. 165:90–99. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G and Gnudi L: Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes. 57:2824–2833. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kosugi T, Nakayama T, Li Q, Chiodo VA, Zhang L, Campbell-Thompson M, Grant M, Croker BP and Nakagawa T: Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am J Physiol Renal Physiol. 298:F609–F616. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves ACh, Gröne HJ, et al: Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med. 14:1857–1867. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 114:898–907. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sonoda H, Ohta H, Watanabe K, Yamashita H, Kimura H and Sato Y: Multiple processing forms and their biological activities of a novel angiogenesis inhibitor vasohibin. Biochem Biophys Res Commun. 342:640–646. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki Y, Kobayashi M, Miyashita H, Ohta H, Sonoda H and Sato Y: Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. J Cell Sci. 123:3094–3101. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kozako T, Matsumoto N, Kuramoto Y, Sakata A, Motonagare R, Aikawa A, Imoto M, Toda A, Honda S, Shimeno H and Soeda S: Vasohibin induces prolyl hydroxylase-mediated degradation of hypoxia-inducible factor-1α in human umbilical vein endothelial cells. FEBS Lett. 586:1067–1072. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sato Y: Novel link between inhibition of angiogenesis and tolerance to vascular stress. J Atheroscler Thromb. 22:327–334. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Miyashita H, Watanabe T, Hayashi H, Suzuki Y, Nakamura T, Ito S, Ono M, Hoshikawa Y, Okada Y, Kondo T and Sato Y: Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PLoS One. 7:e464592012. View Article : Google Scholar : PubMed/NCBI | |
|
Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, Nagata H, Kikuchi E, Nakagawa K, Okada Y, et al: The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 108:2123–2129. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hinamoto N, Maeshima Y, Yamasaki H, Nasu T, Saito D, Watatani H, Ujike H, Tanabe K, Masuda K, Arata Y, et al: Exacerbation of diabetic renal alterations in mice lacking vasohibin-1. PLoS One. 9:e1079342014. View Article : Google Scholar : PubMed/NCBI | |
|
Watatani H, Maeshima Y, Hinamoto N, Yamasaki H, Ujike H, Tanabe K, Sugiyama H, Otsuka F, Sato Y and Makino H: Vasohibin-1 deficiency enhances renal fibrosis and inflammation after unilateral ureteral obstruction. Physiol Rep. 2:e120542014. View Article : Google Scholar : PubMed/NCBI | |
|
He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF and Liu Y: Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD. J Am Soc Nephrol. 23:294–304. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R and Olsen BR: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18:4414–4423. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M and Kalluri R: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA. 100:4766–4771. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K and Makino H: Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 54:2891–2903. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Carlsson AC, Ostgren CJ, Lanne T, Larsson A, Nystrom FH and Arnlov J: The association between endostatin and kidney disease and mortality in patients with type 2 diabetes. Diabetes Metab. 42:351–357. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE and Kalluri R: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem. 275:21340–21348. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A and Kalluri R: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 3:589–601. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y and Makino H: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 53:1831–1840. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, et al: Modification of kidney barrier function by the urokinase receptor. Nat Med. 14:55–63. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin, a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315–328. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang SX, Wang JJ, Lu K, Mott R, Longeras R and Ma JX: Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 17:475–486. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mu W, Long DA, Ouyang X, Agarwal A, Cruz PE, Roncal CA, Nakagawa T, Yu X, Hauswirth WW and Johnson RJ: Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am J Physiol Renal Physiol. 296:F145–F152. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y, Chen A, An SS, Ji RW, Davidson D and Llinas M: Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 272:22924–22928. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang SX, Sima J, Shao C, Fant J, Chen Y, Rohrer B, Gao G and Ma JX: Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia. 47:124–131. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Yao YC, Gu XQ, Che D, Ma CQ, Dai ZY, Li C, Zhou T, Cai WB, Yang ZH, et al: Plasminogen kringle 5 induces endothelial cell apoptosis by triggering a voltage-dependent anion channel 1 (VDAC1) positive feedback loop. J Biol Chem. 289:32628–32638. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jiao X, Zhang D, Hong Q, Yan L, Han Q, Shao F, Cai G, Chen X and Zhu H: Netrin-1 works with UNC5B to regulate angiogenesis in diabetic kidney disease. Front Med. 14:293–304. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pofi R, Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK, Giannakakis K, Morano S, et al: Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Sci Rep. 7:445842017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Hou W, Guan T, Tang L, Zhu X, Li Y, Hou S, Zhang J, Chen H and Huang Y: Slit2/Robo1 signaling is involved in angiogenesis of glomerular endothelial cells exposed to a diabetic-like environment. Angiogenesis. 21:237–249. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hernandez-Diaz I, Pan J, Ricciardi CA, Bai X, Ke J, White KE, Flaquer M, Fouli GE, Argunhan F, Hayward AE, et al: Overexpression of circulating soluble Nogo-B improves diabetic kidney disease by protecting the vasculature. Diabetes. 68:1841–1852. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sulaiman MK: Diabetic nephropathy: Recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 11:72019. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson PC, Wu H, Kirita Y, Uchimura K, Ledru N, Rennke HG, Welling PA, Waikar SS and Humphreys BD: The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc Natl Acad Sci USA. 116:19619–19625. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Berl T: Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection, the case for AT1 receptor antagonist. J Am Soc Nephrol. 15 (Suppl 1):S71–S76. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hilgers KF and Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 13:1100–1108. 2002.PubMed/NCBI | |
|
Zhu X, Wu S, Dahut WL and Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor, systematic review and meta-analysis. Am J Kidney Dis. 49:186–193. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cossey LN, Hennigar RA, Bonsib S, Gown AM and Silva FG: Vascular mesangial channels in human nodular diabetic glomerulopathy. Hum Pathol. 48:148–153. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Elsherbiny NM, El-Sherbiny M and Said E: Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib. J Physiol Biochem. 71:635–648. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Touzani F, Geers C and Pozdzik A: Intravitreal injection of Anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019:29190802019.PubMed/NCBI | |
|
Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, Akladeous N, Bunnapradist S and Gorin MB: Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 12:92–100. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T and Takagi H: Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 139:476–481. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Popescu M, Bogdan C, Pintea A, Rugina D and Ionescu C: Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy. Drug Des Devel Ther. 12:1985–1996. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Senet P: Becaplermin gel (Regranex gel). Ann Dermatol Venereol. 131:351–358. 2004.(In French). View Article : Google Scholar : PubMed/NCBI | |
|
Brem H and Tomic-Canic M: Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 117:1219–1222. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernandez F, Sanchez-Penton P, Morejon-Vega L, Artaza-Sanz H, García-Herrera A, et al: Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: Multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 6:432–443. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T and Furue M: Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 19:461–468. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jude EB, Blakytny R, Bulmer J, Boulton AJ and Ferguson MW: Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med. 19:440–447. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Blakytny R, Jude EB, Martin Gibson J, Boulton AJ and Ferguson MW: Lack of insulin-like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J Pathol. 190:589–594. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Virgili G, Parravano M, Evans JR, Gordon I and Lucenteforte E: Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis. Cochrane Database Syst Rev. 10:CD0074192018.PubMed/NCBI |
